Evidence map›Paper›PMID 40590424›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents.

Jason H Gill, Jonathan D Sellars, Paul G Waddell, Steven D Shnyder, Ronald Grigg, Colin W G Fishwick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jason H GillSchool of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-7564-7787
Jonathan D SellarsSchool of Pharmacy, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-1430-012X
Paul G WaddellChemistry, School of Natural and Environmental Science, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-7851-7347
Steven D ShnyderInstitute of Cancer Therapeutics, School of Life Sciences, University of Bradford, Bradford, UK.ORCID 0000-0002-4647-2340
Ronald GriggSchool of Chemistry, University of Leeds, Leeds, UK.
Colin W G FishwickSchool of Chemistry, University of Leeds, Leeds, UK.ORCID 0000-0003-1283-2181

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small molecule inhibitors of lysine deacetylases (KDACs), exemplified by histone deacetylases (HDACs), exhibit significant promise as cancer therapeutics. Using a modular combinatorial chemistry approach, a novel class of KDAC inhibitors (KDACi) containing the aminophenyl-benzamide headgroup have been developed, which incorporate a vinyl group within the linker region for active site stabilisation and a trifluoromethyl moiety within the capping group to exploit enzyme surface topology. Consequently, a class I selective KDACi (

Indexed as

Antineoplastic AgentsBenzamidesDrug DevelopmentHistone Deacetylase InhibitorsHistone DeacetylasesAnimalsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMiceMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsbenzamideBenzamidesHistone Deacetylase InhibitorsHistone Deacetylasesaminobenzamidebenzamidecancer chemotherapyHDAC Inhibitorhistone deacetylase (HDACs)Lysine Deacetylase (KDACs)protein acetylation

Identifiers

PMID40590424
PMCPMC12217109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.